354 related articles for article (PubMed ID: 27560521)
1. Increased Plasma Matrix Metalloproteinase-9 Levels Contribute to Intracerebral Hemorrhage during Thrombolysis after Concomitant Stroke and Influenza Infection.
Muhammad S; Planz O; Schwaninger M
Cerebrovasc Dis Extra; 2016; 6(2):50-9. PubMed ID: 27560521
[TBL] [Abstract][Full Text] [Related]
2. Increases in circulating matrix metalloproteinase-9 levels following fibrinolysis for acute pulmonary embolism.
Mühl D; Ghosh S; Uzuelli JA; Lantos J; Tanus-Santos JE
Thromb Res; 2010 Jun; 125(6):549-53. PubMed ID: 20307903
[TBL] [Abstract][Full Text] [Related]
3. Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke.
Ning M; Furie KL; Koroshetz WJ; Lee H; Barron M; Lederer M; Wang X; Zhu M; Sorensen AG; Lo EH; Kelly PJ
Neurology; 2006 May; 66(10):1550-5. PubMed ID: 16717217
[TBL] [Abstract][Full Text] [Related]
4. Effects of edaravone, a free radical scavenger, on circulating levels of MMP-9 and hemorrhagic transformation in patients with intravenous thrombolysis using low-dose alteplase.
Tsuruoka A; Atsumi C; Mizukami H; Imai T; Hagiwara Y; Hasegawa Y
J Stroke Cerebrovasc Dis; 2014; 23(10):2894-2899. PubMed ID: 25282183
[TBL] [Abstract][Full Text] [Related]
5. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats.
Sumii T; Lo EH
Stroke; 2002 Mar; 33(3):831-6. PubMed ID: 11872911
[TBL] [Abstract][Full Text] [Related]
6. Recombinant tissue plasminogen activator induces blood-brain barrier breakdown by a matrix metalloproteinase-9-independent pathway after transient focal cerebral ischemia in mouse.
Copin JC; Bengualid DJ; Da Silva RF; Kargiotis O; Schaller K; Gasche Y
Eur J Neurosci; 2011 Oct; 34(7):1085-92. PubMed ID: 21895804
[TBL] [Abstract][Full Text] [Related]
7. MMP9 variation after thrombolysis is associated with hemorrhagic transformation of lesion and death.
Inzitari D; Giusti B; Nencini P; Gori AM; Nesi M; Palumbo V; Piccardi B; Armillis A; Pracucci G; Bono G; Bovi P; Consoli D; Guidotti M; Nucera A; Massaro F; Micieli G; Orlandi G; Perini F; Tassi R; Tola MR; Sessa M; Toni D; Abbate R;
Stroke; 2013 Oct; 44(10):2901-3. PubMed ID: 23908067
[TBL] [Abstract][Full Text] [Related]
8. Extension of the thrombolytic time window with minocycline in experimental stroke.
Murata Y; Rosell A; Scannevin RH; Rhodes KJ; Wang X; Lo EH
Stroke; 2008 Dec; 39(12):3372-7. PubMed ID: 18927459
[TBL] [Abstract][Full Text] [Related]
9. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies.
Horstmann S; Kalb P; Koziol J; Gardner H; Wagner S
Stroke; 2003 Sep; 34(9):2165-70. PubMed ID: 12907822
[TBL] [Abstract][Full Text] [Related]
10. YangXueQingNaoWan attenuated blood brain barrier disruption after thrombolysis with tissue plasminogen activator in ischemia stroke.
Yao SQ; Ye Y; Li Q; Wang XY; Yan L; Huo XM; Pan CS; Fu Y; Liu J; Han JY
J Ethnopharmacol; 2024 Jan; 318(Pt B):117024. PubMed ID: 37572928
[TBL] [Abstract][Full Text] [Related]
11. A Rho kinase (ROCK) inhibitor, fasudil, prevents matrix metalloproteinase-9-related hemorrhagic transformation in mice treated with tissue plasminogen activator.
Ishiguro M; Kawasaki K; Suzuki Y; Ishizuka F; Mishiro K; Egashira Y; Ikegaki I; Tsuruma K; Shimazawa M; Yoshimura S; Iwama T; Hara H
Neuroscience; 2012 Sep; 220():302-12. PubMed ID: 22710066
[TBL] [Abstract][Full Text] [Related]
12. Safety profile of tissue plasminogen activator treatment among stroke patients carrying a common polymorphism (C-1562T) in the promoter region of the matrix metalloproteinase-9 gene.
Montaner J; Fernández-Cadenas I; Molina CA; Monasterio J; Arenillas JF; Ribó M; Quintana M; Chacón P; Andreu AL; Alvarez-Sabín J
Stroke; 2003 Dec; 34(12):2851-5. PubMed ID: 14605329
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinase activation and blood-brain barrier breakdown following thrombolysis.
Kelly MA; Shuaib A; Todd KG
Exp Neurol; 2006 Jul; 200(1):38-49. PubMed ID: 16624294
[TBL] [Abstract][Full Text] [Related]
14. Influenza virus infection aggravates stroke outcome.
Muhammad S; Haasbach E; Kotchourko M; Strigli A; Krenz A; Ridder DA; Vogel AB; Marti HH; Al-Abed Y; Planz O; Schwaninger M
Stroke; 2011 Mar; 42(3):783-91. PubMed ID: 21293018
[TBL] [Abstract][Full Text] [Related]
15. Ascorbic Acid Reduces the Adverse Effects of Delayed Administration of Tissue Plasminogen Activator in a Rat Stroke Model.
Allahtavakoli M; Amin F; Esmaeeli-Nadimi A; Shamsizadeh A; Kazemi-Arababadi M; Kennedy D
Basic Clin Pharmacol Toxicol; 2015 Nov; 117(5):335-9. PubMed ID: 25899606
[TBL] [Abstract][Full Text] [Related]
16. Progesterone attenuates hemorrhagic transformation after delayed tPA treatment in an experimental model of stroke in rats: involvement of the VEGF-MMP pathway.
Won S; Lee JH; Wali B; Stein DG; Sayeed I
J Cereb Blood Flow Metab; 2014 Jan; 34(1):72-80. PubMed ID: 24045404
[TBL] [Abstract][Full Text] [Related]
17. Transient brain hypothermia reduces the reperfusion injury of delayed tissue plasminogen activator and extends its therapeutic time window in a focal embolic stroke model.
Zarisfi M; Allahtavakoli F; Hassanipour M; Khaksari M; Rezazadeh H; Allahtavakoli M; Taghavi MM
Brain Res Bull; 2017 Sep; 134():85-90. PubMed ID: 28710023
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke.
Montaner J; Molina CA; Monasterio J; Abilleira S; Arenillas JF; Ribó M; Quintana M; Alvarez-Sabín J
Circulation; 2003 Feb; 107(4):598-603. PubMed ID: 12566373
[TBL] [Abstract][Full Text] [Related]
19. Fibrinogen decrease after intravenous thrombolysis in ischemic stroke patients is a risk factor for intracerebral hemorrhage.
Vandelli L; Marietta M; Gambini M; Cavazzuti M; Trenti T; Cenci MA; Casoni F; Bigliardi G; Pentore R; Nichelli P; Zini A
J Stroke Cerebrovasc Dis; 2015 Feb; 24(2):394-400. PubMed ID: 25497721
[TBL] [Abstract][Full Text] [Related]
20. Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia.
Liu W; Hendren J; Qin XJ; Liu KJ
Stroke; 2009 Jul; 40(7):2526-31. PubMed ID: 19478225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
